TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05226130

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical transcutaneous vagus nerve stimulation (active comparator)
Description: Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cervical transcutaneous vagus nerve stimulation (sham comparator)
Description: Sham nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that does not stimulate the vagus nerve.
Study: NCT06532045

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: TENS applied for 30 min for each time, five times a week, for 2 weeks and deep breathing relaxation exercise given to the intervention group twice a day (10min/exercise) for two weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: TENS applied for 30 min for each time, five times a week, for 2 weeks and deep breathing relaxation exercise given to the intervention group twice a day (10min/exercise) for two weeks.
Study: NCT06535113

Intervention type: OTHER
Intervention: Clinical Practice
Description: All the procedures in Study will be conducted as per Clinical practice for the pathology and all the samples will be collected according to ELN guidelines.~There are no additional procedures but will be additionally collected up 20ml of peripheral blood and up to 15ml of Bone Marrow Aspirate at the same time of clinically indicated diagnostic procedures.
Study: NCT05257889

Intervention type: DIAGNOSTIC_TEST
Intervention: blood and CSF studies + neuroimaging studies
Description: blood and CSF studies + neuroimaging studies

Intervention type: DIAGNOSTIC_TEST
Intervention: blood and CSF studies + neuroimaging studies
Description: blood and CSF studies + neuroimaging studies
Study: NCT05747677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 Nasal Spray
Description: HH-120 nasal spray, 1 spray to each nostril of the participant each time,8-10 times per day, until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.
Study: NCT05278949

Intervention type: OTHER
Group type: OTHER
Intervention: The surgical intervention
Description: The participant's primary IOL is re-fixed without utilizing any new material.
Study: NCT05368805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib will be administered as a single oral 5mg dose on the morning of day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib will be administered as a single oral 5mg dose on the morning of day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Dabigatran Etexilate will be administered as a single oral dose 150mg on the morning of day 1 and morning of day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin will be administered as a single oral dose 10mg on the morning of day 1 and the morning of day 5
Study: NCT05793905

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine in inferior alveolar nerve block injection
Description: Buffered Lidocaine 2% with epinephrine 1.80000 mixed with 1.8% sodium bicarbonate in IANB injection in the treatment of bilateral primary mandibular molars

Intervention type: DRUG
Group type: OTHER
Intervention: lidocaine 2% in inferior alveolar nerve block injection
Description: Lidocaine 2% with epinephrine 1.80000 in IANB injection in the treatment of bilateral primary mandibular molars
Study: NCT05436574

Intervention type: OTHER
Group type: OTHER
Intervention: Dance therapy
Description: Before/after study to measure the effects of the dance therapy activity on the quality of life of the elderly population housed in the establishments of UNIVI group.
Study: NCT06446635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semiflex Dome Catheter System
Description: Abces: In patients that present with a perianal abscess/sinus the semiflex dome catheter is inserted under general anesthesia. A small cut is made to drain and irrigate the septic sinus.~Fistula: Under general anesthesia the seton is removed, the internal opening is excised and the internal opening is closed with a 2-0 Vicryl cross stitch.~Both: Before surgery, the length of the tract is measured on MRI or CT. A Semiflex Catheter with the appropriate length and a diameter is selected. If during surgery appears that this is not the appropriate size, a different size catheter can be used. The catheter is fixed on a Renasys Adhesive gel patch (Smith and Nephew). The catheter is connected with a tubing system to a vacuum pomp with an average vacuum pressure of 80 cm H2O. The tube will be taped on the patient. After every 2-3 days the catheter will be exchanged by a 3-6 mm shorter catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semiflex Dome Catheter System
Description: Abces: In patients that present with a perianal abscess/sinus the semiflex dome catheter is inserted under general anesthesia. A small cut is made to drain and irrigate the septic sinus.~Fistula: Under general anesthesia the seton is removed, the internal opening is excised and the internal opening is closed with a 2-0 Vicryl cross stitch.~Both: Before surgery, the length of the tract is measured on MRI or CT. A Semiflex Catheter with the appropriate length and a diameter is selected. If during surgery appears that this is not the appropriate size, a different size catheter can be used. The catheter is fixed on a Renasys Adhesive gel patch (Smith and Nephew). The catheter is connected with a tubing system to a vacuum pomp with an average vacuum pressure of 80 cm H2O. The tube will be taped on the patient. After every 2-3 days the catheter will be exchanged by a 3-6 mm shorter catheter.
Study: NCT05306652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised physical activity
Description: patients will have a home-based physical activity prescription, defined on the functional endurance and strength tests and they will be supervised for 3 months. Once monthly they will be examined by the oncologist (visit and questionnaires) and at weeks 4, 6, 8, 10 and 12 at the sport medicine center where the three tests will be repeated. Home-based activity will be monitored daily through a specific application. Endurance improvement is defined as an increase in walking speed; strength improvement is defined as an increase of the number of repetitions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised physical activity
Description: patients will receive a physical activity counselling, without a real prescription and supervision, and the three test will be repeated once a month for three months at the local sport medicine center and at the oncology center (visit and questionnaires). Counselling will include general informations on physical exercise
Study: NCT05729074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment
Description: Drug: IN-A002 Ointment 0.3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment
Description: Drug: IN-A002 Ointment 0.5%, 10 g/1000 cm2, for 1 day Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2, for 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002 Ointment 1% or IN-A002 Placebo Ointment
Description: Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002 Ointment 1% or IN-A002 Placebo Ointment
Description: Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002 Ointment 3% or IN-A002 Placebo Ointment
Description: Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002 Ointment 3% or IN-A002 Placebo Ointment
Description: Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002 Ointment 5% or IN-A002 Placebo Ointment
Description: Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002 Ointment 5% or IN-A002 Placebo Ointment
Description: Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002 Ointment 1%
Description: Drug: IN-A002 Ointment 1%, 3 g/1000 cm2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002 Ointment 3%
Description: Drug: IN-A002 Ointment 3%, 3 g/1000 cm2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elidel Cream 1% (pimecrolimus)
Description: Drug: Elidel Cream 1% (pimecrolimus), 3 g/1000 cm2
Study: NCT05297045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT001-075
Description: Oral GLP1 Receptor Agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT001-075
Description: Oral GLP1 Receptor Agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT001-075
Description: Oral GLP1 Receptor Agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT001-075
Description: Oral GLP1 Receptor Agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT001-075
Description: Oral GLP1 Receptor Agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT001-075
Description: Oral GLP1 Receptor Agonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT06260657

Intervention type: OTHER
Intervention: Histological analysis on fetal ethmoids
Description: Immunohistological analysis (immunohistochemical or immunofluorescent) on fetal ethmoids
Study: NCT06126055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Band Ligation
Description: Placing bands in distal esophagus
Study: NCT05145231

Intervention type: OTHER
Intervention: observational
Description: The scales will be filled by asking the family.
Study: NCT06664203

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective turuncus block with 25 ml bupivacain
Description: A high-frequency linear ultrasound (USG) probe will be used to locate the C7 transverse process, which will serve as a sonoanatomic landmark. Once the C5 ventral ramus is identified at the C7 transverse process level, the linear probe will be slightly caudally angled to visualize the C6 ventral ramus. The area where the superior trunk is formed by C5 and C6 will be examined with the USG probe until the superior trunk is visualized. Below the superior trunk, the middle trunk and the C8 ventral ramus will be visible. In Group 1, a total of 23 ml of 0.5% bupivacaine plus 2 ml (8 mg dexamethasone) will be used as the local anesthetic mixture, totaling 25ml. 7ml of the local anesthetic mixture will be injected into the superior trunk, the middle trunk for an additional 8 ml. The probe will then be directed caudally to obtain an optimal view of the lower trunk, where 10 ml of the same mixture will be injected close to the lower trunk.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective turuncus block with 15 ml bupivacain
Description: In Group 2, 13 ml of 0.5% bupivacaine plus 2 ml (8 mg dexamethasone) will be used, totaling 15 ml. In Group 2, 5 ml of the local anesthetic mixture will be injected into the superior trunk, followed by 5 ml into the middle trunk and 5 ml into the lower trunk, as in Group II.
Study: NCT06658340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positivity in Post-COVID
Description: A training to support well-being and self-management in patients with post-COVID-19 syndrome
Study: NCT06663306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intrathecal pemetrexed 50mg,twice per week (d1, d8) for 1 week, then once per 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intrathecal pemetrexed 50mg,twice per week (d1, d8) for 1 week, then once per 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intrathecal bevacizumab, once (d8)for 1 week, then once per 4 weeks.The initial dose of intrathecal bevacizumab is 5 mg, escalated to 10 mg, and then 25 mg, and then 37.5mg, and then 50mg.
Study: NCT05819749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Homelessness Medication Support Program in Spanish
Description: There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief diabetes education as needed.
Study: NCT06460311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEDAL and EMS
Description: Group A will receive EMS with Stationary cycle. EMS will be given at quadricep muscles. The pads will placed vertically in the midline along the knee and the pelvis. EMS will be given at frequency = 35 to 70 Hz, pulse duration = 100 μs, pulse period = 50 ms, Intervention will be will be performed for 60 minutes for 3 times or week for 4 weeks.~Conversely, the endurance training phase will involve securing the cycle seat while children cycle at their maximum capacity, aiming for a heart rate between 70% to 80% of their maximum. Prior to and following each session, stretching exercises targeting the calf, quadricep, and hamstring muscles will be administered, with a 10-second hold during both the warm-up and cool-down sessions. Pre and post measurements will be conducted to evaluate mobility and gait

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEDAL
Description: In Group B, participants will exclusively receive the Pediatric Endurance and Limb Strengthening program without EMS. Similar to Group A, this program will incorporate the use of a stationary cycle. The warm-up and cool-down periods will also include a 10-second hold for each targeted muscle group. The intervention will consist of 60-minute sessions conducted three times per week over a span of four weeks.~Pre and post-assessments of gait and mobility will be conducted using the Gait Outcomes Assessment List (GOALTM) Questionnaire and the time up and go test.
Study: NCT06539143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: The Paracervical Block with lidocaine for manual vacuum aspiration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The Paracervical Block with lidocaine for manual vacuum aspiration
Study: NCT05630716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICOM
Description: non-invasive monitor capable of measuring cardiac output (CO) and cardiac index (CI), and stroke volume (SV) and stroke volume index (SVI) based on heart rate. The NICOM technology will be implemented by the Rapid Response Team providers (Advanced Practice Providers) and ICU nurses at FSH, most of whom are already trained and familiar with its use.
Study: NCT06111092

Intervention type: OTHER
Group type: OTHER
Intervention: Design Thinking
Description: Participants attend the DT session through all the stages that include emphasize, define, ideate, prototype and test.

Intervention type: OTHER
Group type: OTHER
Intervention: Focus Groups
Description: Participants attend the FG that includes the introduction. discussion, and reflection.
Study: NCT05872230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Massage Percussion Therapy device
Description: Using massage percussion postoperatively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Massage Percussion Therapy device
Description: Using massage percussion postoperatively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Massage Percussion Therapy device
Description: Using massage percussion postoperatively.
Study: NCT04803773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UFOGUIDE patient transducer
Description: The transducer is maintained by a flexible/rigid structure, consisting of a support base, and three to four feet forming an arch around the area to be treated. These feet exist in several lengths (10, 20, 30, 40 cm) depending on the area to be treated and can be easily mounted on the base by fast attachment. The structure is based on the principle of granular jamming: it is flexible in its normal state, and can be stiffened by the application of depression within the feet.
Study: NCT06376773

Intervention type: PROCEDURE
Intervention: combination chemotherapy with Apatinib or Camrelizumab
Description: Apatinib, chemotherapy alone, Camrelizumab

Intervention type: PROCEDURE
Intervention: combination chemotherapy with Apatinib or Camrelizumab
Description: Apatinib, chemotherapy alone, Camrelizumab
Study: NCT05385796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loop taping
Description: The participant lays prone on the treatment table with his/her feet dangling off the table. The physiotherapist cleans the heel with alcohol wipes. Care is taken to avoid erasing skin markings for respective algometer and ultrasound assessment by these wipes. The therapist applies 1-inch-width Elastikon tape around the heel, encircling and bunching the fat pad to centralize it and enhance its fullness and resilience to compression. The tape starts at the middle distal end of the fat pad and loop around the periphery and ends by crossing the starting point at the middle distal end of the fat pad. Two to three overlapping loops will be applied to ensure strong support during weight-bearing activities. Participants will be instructed to wear the loop taping for 3 days and remove the taping after responding to an online survey 3-days post intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control taping
Description: The participant lays prone on the treatment table with his/her feet dangling off the table. The physiotherapist cleans the heel with alcohol wipes. The therapist applies 1-inch-width Elastikon tape around the heel, lightly encircling the heel fat pad without any force/pressure or attempt to bunch or centralize the fat pad. The tape starts at the middle distal end of the fat pad and loop around the periphery and ends by crossing the starting point at the middle distal end of the fat pad. Two to three overlapping loops will be applied. Participants will be instructed to wear the control taping for 3 days and remove the taping after responding to an online survey 3-days post intervention.
Study: NCT06542692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: treatment duration, frequency

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: physical therapy modalities
Description: ultrasound, hot pack, tens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: physical therapy modalities
Description: ultrasound, hot pack, tens
Study: NCT06140537

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tablet orally daily
Study: NCT05667688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinlarebant (LBS-008)
Description: A single dose of Tinlarebant (LBS-008) will be administered to each study participant on study Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinlarebant (LBS-008)
Description: A single dose of Tinlarebant (LBS-008) will be administered to each study participant on study Day 1.
Study: NCT06036173

Intervention type: OTHER
Intervention: diagnosis of lymphedema
Description: being diagnosed with secondary lymphedema in the upper extremity according to the International Lymphedema Association

Intervention type: OTHER
Intervention: breast cancer surgery
Description: be diagnosed and undergo surgery

Intervention type: OTHER
Intervention: breast cancer surgery
Description: be diagnosed and undergo surgery
Study: NCT06523309

Intervention type: OTHER
Intervention: Electroacupuncture treatment
Description: Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated.

Intervention type: OTHER
Intervention: Electroacupuncture treatment
Description: Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated.

Intervention type: OTHER
Intervention: Electroacupuncture treatment
Description: Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated.

Intervention type: OTHER
Intervention: Electroacupuncture treatment
Description: Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated.
Study: NCT06536218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION
Description: CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION Conscious Awareness Based Stress Reduction (BFTSA) intervention consists of seven sessions in total and is planned to be completed in a total of seven weeks, with one session per week and each session being 45 minutes. After the results of the PSG patients are determined according to the randomization criteria, they receive certain points from the sleep scale, it is planned to call the patients by phone and explain the meaning and importance of the study, the applications to be performed in the study and its duration. It is planned to hold online individual interviews with patients who agree to participate in this study.
Study: NCT05264038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC514 (Low dose)
Description: Low dose level of OC514
Study: NCT06025786

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Benazir Nashonuma Program (BNP)
Description: Benazir Nashonuma Program (BNP)~Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy.~Conditional Cash Transfer (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months